GANXHealthcare · BiotechnologyThe 5 Wall Street analysts covering Gain Therapeutics, Inc. hold a median 12-month price target of $8 — +395.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Gain Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (79): Smaller than most of the companies we track.
Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on GANX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +395.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 31 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 11 Aug 2026 | BTIG | Reiterates | Buy | $5.00 |
| 11 Aug 2026 | BTIG | Reiterates | Buy | — |
| 1 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 1 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 June 2026 | BTIG | Maintains | Buy | $5.00 |
| 30 June 2026 | BTIG | Maintains | Buy | — |
| 19 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Oct 2025 | BTIG | Reiterates | Buy | — |
| 13 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Oct 2025 | Maxim Group | Maintains | Buy | — |
| 8 Sept 2025 | BTIG | Reiterates | Buy | — |
| 13 Aug 2025 | Roth Capital | Maintains | Buy | — |
| 3 July 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 17 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | Scotiabank | Initiates | Sector Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GANX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Gain Therapeutics, Inc. returned −22.0% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 16% of US stocks
Cheaper than 76% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 6% of US stocks
Higher than 3% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Gain Therapeutics, Inc. has a market value of $70.5M and an enterprise value of $58.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$20.1M.
Free cash flow in the twelve months to 30 June 2026: −$19.0M.
Trailing P/E: −2.6×; forward P/E: −2.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Gain Therapeutics, Inc. employs 20 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Gain Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Gain Therapeutics announced that it will participate in the 2026 Maxim Growth Summit, scheduled for October 12–14 at The Hard Rock Hotel New York in New York City.
Why it matters — GANX watchers may note the company’s planned participation in an upcoming investor-focused summit.
Gain Therapeutics presented positive Phase 1b open-label extension data for rexaceract, showing further evidence of disease-modifying activity through 12 months of administration. Among the 12 evaluable participants who completed 12 months of daily oral dosing by August 31, 2026, MDS-UPDRS motor scores demonstrated stability to baseline with no disease progression.
Why it matters — GANX watchers would care because the data provide additional evidence supporting rexaceract's potential disease-modifying activity, a key milestone for the company's lead Parkinson's disease candidate.
Gain Therapeutics announced a poster presentation at the International Congress of Parkinson's Disease and Movement Disorders, to be held October 4-8, 2026, in Seoul, Korea. The company described itself as a clinical-stage biotechnology firm focused on developing the next generation of allosteric small molecule therapies.
Why it matters — A poster presentation at a major international Parkinson's conference signals research visibility and potential scientific engagement for GANX in its therapeutic area.
Gain Therapeutics announced that President and CEO Gene Mack will participate in an industry panel and one-on-one meetings at the ROTH Fifth Annual Healthcare Opportunities Conference, to be held September 29 at the Metropolitan Club in New York. The company is a clinical-stage biotechnology firm focused on allosteric small molecule therapies.
Why it matters — The CEO's participation and investor meetings at a healthcare conference could raise Gain Therapeutics' visibility with investors and the broader biotech community.
Gain Therapeutics announced that President and CEO Gene Mack will participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference. The announcement was made on August 25, 2026.
Why it matters — A GANX watcher would care because the CEO's participation at a major investment conference provides an opportunity for the company to present its pipeline to investors and analysts.
The 5 Wall Street analysts covering Gain Therapeutics, Inc. have a median 12-month price target of $8, with estimates ranging from $5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Gain Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Gain Therapeutics, Inc. 31 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Gain Therapeutics, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +395.4% from the last close, and Ticker Nerd's factor model ranks Gain Therapeutics, Inc. 31 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Gain Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GANX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $8 over the next 12 months.
Gain Therapeutics, Inc. returned -22.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing allosteric small molecule therapies for difficult-to-treat diseases.
The most recent item we track (GlobeNewsWire, 8 Oct 2026): "Gain Therapeutics to Attend the 2026 Maxim Growth Summit". Gain Therapeutics announced that it will participate in the 2026 Maxim Growth Summit, scheduled for October 12–14 at The Hard Rock Hotel New York in New York City.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing allosteric small molecule therapies for difficult-to-treat diseases. Its current research centers on neurodegenerative disorders and other conditions linked to protein misfolding, with a particular emphasis on Parkinson’s disease and select rare genetic diseases. The company’s lead candidate, GT-02287, is being evaluated for Parkinson’s disease and is part of a broader pipeline aimed at addressing underlying disease mechanisms rather than only managing symptoms. Gain Therapeutics also uses its Magellan drug discovery platform to identify novel allosteric binding sites and design proprietary compounds with the potential to modulate protein function. Headquartered in Bethesda, Maryland, Gain Therapeutics operates as a specialized player in precision medicine and computational drug discovery within the biotechnology sector.
CEO Mr. Gene Mack M.B.A. · 20 employees · United States · https://gaintherapeutics.com
